Clinical Trials Directory

Trials / Sponsors / Geneplus-Beijing Co. Ltd.

Geneplus-Beijing Co. Ltd.

Industry · 12 registered clinical trials6 currently recruiting.

StatusTrialPhaseStarted
RecruitingApplication of CfDNA Methylation Detection in Auxiliary Diagnosis of Breast Cancer
Breast Cancer Screening
2025-03-15
Not Yet RecruitingThe Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer
Ovarian Cancer
2024-12-01
RecruitingCirculating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR
Colorectal Cancer
2023-10-30
CompletedBenign/Malignant Pulmonary Nodule Classification Based on High-throughput Whole-genome Methylation Sequencing(
Pulmonary Nodule, Solitary, Whole-genome Methylation Sequencing
2023-07-01
RecruitingExploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Lung Cancer
2023-06-19
WithdrawnTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
2021-12-20
RecruitingTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung
2020-07-01
RecruitingctDNA Monitoring in Early Breast Cancer
Breast Cancer
2019-11-29
Active Not RecruitingThe PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
Early Detection of Cancer
2019-11-12
UnknownThe Tracking Molecular Evolution for NSCLC (T-MENC) Study
Lung Neoplasms, Lung Cancer, Nonsmall Cell Lung Cancer
2018-11-06
Active Not RecruitingAssessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
Ovarian Cancer
2017-11-25
CompletedTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China
Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung
2017-02-22